Nuvalent Inc.

This program offers early access to the investigational drug neladalkib for people with advanced ALK-positive lung cancer or other ALK-positive solid tumors who have run out of standard treatment options and cannot join a clinical trial. Participants must be at least 18 years old…

This expanded access program provides the investigational drug zidesamtinib (NVL-520) to adults with advanced ROS1-positive non-small cell lung cancer or other solid tumors who have no satisfactory treatment options and cannot join a clinical trial. Participants must have receive…

This phase 3 study compares a new drug, NVL-655, to the standard treatment alectinib in people with advanced ALK-positive non-small cell lung cancer who have not had prior therapy. About 450 participants will be randomly assigned to receive either NVL-655 or alectinib. The main g…

This study tests a new drug called neladalkib (NVL-655) in people with advanced ALK-positive non-small cell lung cancer and other solid tumors. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks how well it shrinks tumors. Up to 840 participants will be en…

This early-phase study tests a new oral drug, NVL-330, in about 200 adults with advanced or metastatic non-small cell lung cancer that has specific HER2 mutations. The goal is to find the safest and most effective dose and see if the drug can shrink tumors. Participants must have…

This study tests a new drug called zidesamtinib (NVL-520) for people with advanced lung cancer or other solid tumors that have a specific genetic change (ROS1-positive). The goal is to find the best dose and see how well it shrinks tumors. About 359 adults will take part in two p…